EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer

Munawaer Muaibati, Abasi Abuduyilimu, Tao Zhang, Yun Dai, Ruyuan Li, Fanwei Huang, Kexin Li, Qing Tong, Xiaoyuan Huang, Liang Zhuang iD

Expert Reviews in Molecular Medicine · 2023

DOI: 10.1017/erm.2023.3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, 2023. Verfasst von Munawaer Muaibati und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ovarian Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 158 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the most lethal female reproductive system tumour. Despite the great advances in surgery and systemic chemotherapy over the past two decades, almost all patients in stages III and IV relapse and develop resistance to chemotherapy after first-line treatment. Ovarian cancer has an extraordinarily complex immunosuppressive tumour microenvironment in which immune checkpoints negatively regulate T cells activation and weaken antitumour immune responses by delivering immunosuppressive signals. Therefore, inhibition of immune checkpoints can break down the state of immunosuppression. Indeed, Immune checkpoint inhibitors (ICIs) have revolutionised the therapeutic landscape of many solid tumours. However, ICIs have yielded modest benefits in ovarian cancer. Therefore, a more comprehensive understanding of the mechanistic basis of the immune checkpoints is needed to improve the efficacy of ICIs in ovarian cancer. In this review, we systematically introduce the mechanisms and expression of immune checkpoints in ovarian cancer. Moreover, this review summarises recent updates regarding ICI monotherapy or combined with other small-molecule-targeted agents in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsOvarian NeoplasmsHumansFemaleImmune Checkpoint InhibitorsImmunotherapyNeoplasm Recurrence, LocalTumor Microenvironment

Stichwörter der Autor:innen

Immune checkpoint inhibitors (ICIs)immune checkpointovarian cancertargeted therapytumour microenvironment

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Department of Gynecology and Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

ORCID-Profile: Liang Zhuang

Zitieren

APA

Muaibati, M., Abuduyilimu, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023). Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer. Expert Reviews in Molecular Medicine. https://doi.org/10.1017/erm.2023.3

Vancouver

Muaibati M, Abuduyilimu A, Zhang T, Dai Y, Li R, Huang F, et al. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer. Expert Reviews in Molecular Medicine. 2023. doi:10.1017/erm.2023.3

BibTeX
@article{Muaibati2023,
  author = {Muaibati, Munawaer and Abuduyilimu, Abasi and Zhang, Tao and Dai, Yun and Li, Ruyuan and Huang, Fanwei and Li, Kexin and Tong, Qing and Huang, Xiaoyuan and Zhuang, Liang},
  title = {Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer},
  journal = {Expert Reviews in Molecular Medicine},
  year = {2023},
  doi = {10.1017/erm.2023.3}
}
Kostenlos starten →